Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).

Inna Markovna ChenJulia S JohansenSusann TheileJessica X HjaltelinSif Ingibergsdóttir Novitski Soren Brunak Jane P Hasselby Gro L WillemoeTorben LorentzenKasper MadsenBenny V JensenEva E WilkenPoul GeertsenClaus Preibisch Behrens Christian Pállson NolsøeKirstine L HermannInge Marie Svane Dorte Lisbet Nielsen

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Clinically meaningful antitumor activity and favorable safety profiles were demonstrated after treatment with SBRT/nivolumab/ipilimumab in patients with refractory mPC. However, the contribution from SBRT is unknown. Further studies are warranted.

Keyphrases

phase ii study
radiation therapy
locally advanced
open label
placebo controlled
squamous cell carcinoma
double blind
phase iii
phase ii
small cell lung cancer
early stage
rectal cancer
radiation induced
clinical trial
study protocol